Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.

Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer.

<h4>Objectives</h4>Adjuvant paclitaxel and trastuzumab has been shown to be an effective regimen with low risk of cancer recurrence and treatment-related toxicities in early-stage node-negative, HER2-positive breast cancer. We investigated the cost-effectiveness of this regimen.<h4>...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali Hajjar, Mehmet A Ergun, Oguzhan Alagoz, Murtuza Rampurwala
Formato: Artículo
Lenguaje:English
Publicado: Public Library of Science (PLoS) 2019-01-01
Colección:PLoS ONE
Acceso en línea:https://doi.org/10.1371/journal.pone.0217778

Ejemplares similares

Ejemplares similares